We have previously shown that TRAIL death receptors, with a higher incident in DR4, undergo constitutive endocytosis in breast cancer cells that results in their deficiency on cell surface and cellular resistance to the targeted therapies [21-23]. This evidence concerns the gene TNFRSF10A and breast carcinoma.